Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$382.68 6.82 (1.81)%

High 383.95 Low 373.27 Volume 547,794 Market Cap 40.38B
01/23/18 2:46 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Jan 23

    Forty of the Nation's Most Promising Young Scientists Named Finalists in Regeneron Science Talent Search 2018

    Read on
  • Jan 22

    Regeneron Announces Approval of DUPIXENT® (dupilumab) in Japan for the Treatment of Atopic Dermatitis

    Read on

EVENTS

  • 36th Annual J.P. Morgan Healthcare Conference Q&A
    Jan 8, 2018 | 12:00 PM PT

  • 36th Annual J.P. Morgan Healthcare Conference
    Jan 8, 2018 | 11:30 AM PT

Events & Presentations

NASDAQ REGN

$382.68 6.82 (1.81)%

High 383.95 Low 373.27 Volume 547,794 Market Cap 40.38B
01/23/18 2:46 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information